JPWO2021081133A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021081133A5 JPWO2021081133A5 JP2022523383A JP2022523383A JPWO2021081133A5 JP WO2021081133 A5 JPWO2021081133 A5 JP WO2021081133A5 JP 2022523383 A JP2022523383 A JP 2022523383A JP 2022523383 A JP2022523383 A JP 2022523383A JP WO2021081133 A5 JPWO2021081133 A5 JP WO2021081133A5
- Authority
- JP
- Japan
- Prior art keywords
- binding domain
- fragment
- cell
- receptor
- polynucleotide construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002157 polynucleotide Substances 0.000 claims description 52
- 102000040430 polynucleotide Human genes 0.000 claims description 52
- 108091033319 polynucleotide Proteins 0.000 claims description 52
- 210000004027 cell Anatomy 0.000 claims description 50
- 239000012634 fragment Substances 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 34
- 102000005962 receptors Human genes 0.000 claims description 28
- 108020003175 receptors Proteins 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 19
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 18
- 230000011664 signaling Effects 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 239000012822 autophagy inhibitor Substances 0.000 claims description 11
- -1 NKp40 Proteins 0.000 claims description 10
- 230000003213 activating effect Effects 0.000 claims description 10
- 208000005017 glioblastoma Diseases 0.000 claims description 10
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 9
- 229960005305 adenosine Drugs 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 8
- 231100000433 cytotoxic Toxicity 0.000 claims description 8
- 230000001472 cytotoxic effect Effects 0.000 claims description 8
- 102000018697 Membrane Proteins Human genes 0.000 claims description 7
- 108010052285 Membrane Proteins Proteins 0.000 claims description 7
- 210000000822 natural killer cell Anatomy 0.000 claims description 7
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 6
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 208000003837 Second Primary Neoplasms Diseases 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 229960003677 chloroquine Drugs 0.000 claims description 6
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 108020001756 ligand binding domains Proteins 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 6
- 150000003384 small molecules Chemical class 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- SPDQRCUBFSRAFI-DOMZBBRYSA-N (8s)-9-[(5-chloropyridin-3-yl)methyl]-2-[(3r)-3-methylmorpholin-4-yl]-8-(trifluoromethyl)-7,8-dihydro-6h-pyrimido[1,2-a]pyrimidin-4-one Chemical compound C[C@@H]1COCCN1C1=CC(=O)N(CC[C@H](N2CC=3C=C(Cl)C=NC=3)C(F)(F)F)C2=N1 SPDQRCUBFSRAFI-DOMZBBRYSA-N 0.000 claims description 4
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims description 4
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 4
- 101710178046 Chorismate synthase 1 Proteins 0.000 claims description 4
- 101710152695 Cysteine synthase 1 Proteins 0.000 claims description 4
- 101150029707 ERBB2 gene Proteins 0.000 claims description 4
- 102400001368 Epidermal growth factor Human genes 0.000 claims description 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 4
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 4
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 4
- 102100032831 Protein ITPRID2 Human genes 0.000 claims description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 4
- 101000972274 Sus scrofa Apomucin Proteins 0.000 claims description 4
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 claims description 4
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 claims description 4
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
- 230000004642 autophagic pathway Effects 0.000 claims description 4
- CFDVGUXRLQWLJX-QGTNPELVSA-N beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)C(O)O[C@@H]1CO CFDVGUXRLQWLJX-QGTNPELVSA-N 0.000 claims description 4
- 230000001461 cytolytic effect Effects 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- 229940116977 epidermal growth factor Drugs 0.000 claims description 4
- 150000002270 gangliosides Chemical class 0.000 claims description 4
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 4
- 230000000503 lectinlike effect Effects 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 101150047061 tag-72 gene Proteins 0.000 claims description 4
- 108091008578 transmembrane receptors Proteins 0.000 claims description 4
- 102000027257 transmembrane receptors Human genes 0.000 claims description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 4
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 claims description 4
- 229960003895 verteporfin Drugs 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 claims description 2
- 108010085238 Actins Proteins 0.000 claims description 2
- 108010061408 Autophagy-Related Protein 12 Proteins 0.000 claims description 2
- 102000012035 Autophagy-Related Protein 12 Human genes 0.000 claims description 2
- 108010092776 Autophagy-Related Protein 5 Proteins 0.000 claims description 2
- 102000016614 Autophagy-Related Protein 5 Human genes 0.000 claims description 2
- 108010092778 Autophagy-Related Protein 7 Proteins 0.000 claims description 2
- 102000016613 Autophagy-Related Protein 7 Human genes 0.000 claims description 2
- 108010014380 Autophagy-Related Protein-1 Homolog Proteins 0.000 claims description 2
- 102100040355 Autophagy-related protein 16-1 Human genes 0.000 claims description 2
- 102100021251 Beclin-1 Human genes 0.000 claims description 2
- 102100038077 CD226 antigen Human genes 0.000 claims description 2
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims description 2
- 102000015212 Fas Ligand Protein Human genes 0.000 claims description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000964092 Homo sapiens Autophagy-related protein 16-1 Proteins 0.000 claims description 2
- 101000894649 Homo sapiens Beclin-1 Proteins 0.000 claims description 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 2
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims description 2
- 101000607332 Homo sapiens Serine/threonine-protein kinase ULK2 Proteins 0.000 claims description 2
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 102000009565 Lysosomal-Associated Membrane Protein 2 Human genes 0.000 claims description 2
- 108010009491 Lysosomal-Associated Membrane Protein 2 Proteins 0.000 claims description 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 101800001821 Precursor of protein E3/E2 Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100023588 RB1-inducible coiled-coil protein 1 Human genes 0.000 claims description 2
- 101710189963 RB1-inducible coiled-coil protein 1 Proteins 0.000 claims description 2
- 102100020814 Sequestosome-1 Human genes 0.000 claims description 2
- 102100039988 Serine/threonine-protein kinase ULK1 Human genes 0.000 claims description 2
- 102100039987 Serine/threonine-protein kinase ULK2 Human genes 0.000 claims description 2
- 101710165434 Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 238000011467 adoptive cell therapy Methods 0.000 claims description 2
- 230000003828 downregulation Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 101800002664 p62 Proteins 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 238000002619 cancer immunotherapy Methods 0.000 claims 2
- 230000002601 intratumoral effect Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962923644P | 2019-10-21 | 2019-10-21 | |
| US62/923,644 | 2019-10-21 | ||
| PCT/US2020/056723 WO2021081133A1 (en) | 2019-10-21 | 2020-10-21 | Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022553292A JP2022553292A (ja) | 2022-12-22 |
| JP2022553292A5 JP2022553292A5 (https=) | 2024-01-04 |
| JPWO2021081133A5 true JPWO2021081133A5 (https=) | 2024-01-04 |
Family
ID=75620220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523383A Pending JP2022553292A (ja) | 2019-10-21 | 2020-10-21 | 操作されたナチュラルキラー細胞、ならびに免疫療法およびオートファジー阻害技法においてそれを使用するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220362299A1 (https=) |
| EP (1) | EP4048292A4 (https=) |
| JP (1) | JP2022553292A (https=) |
| AU (1) | AU2020371628A1 (https=) |
| CA (1) | CA3155246A1 (https=) |
| WO (1) | WO2021081133A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| CN113621073A (zh) * | 2021-07-14 | 2021-11-09 | 上海易慕峰生物科技有限公司 | 一种新型嵌合受体组合物、重组载体、细胞及其应用 |
| CN120459135B (zh) * | 2025-07-16 | 2025-10-10 | 深圳市中佳生物医疗科技有限公司 | Cd73+nk细胞在制备预防或治疗帕金森的药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2948544A4 (en) * | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| GB201403972D0 (en) * | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| EP3218407A1 (en) * | 2014-11-11 | 2017-09-20 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
| MY189836A (en) * | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| WO2017172981A2 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| WO2017186121A1 (zh) * | 2016-04-26 | 2017-11-02 | 科济生物医药（上海）有限公司 | 一种改善免疫应答细胞功能的方法 |
| US20180100016A1 (en) * | 2016-12-22 | 2018-04-12 | Xiaotong Song | Use of car-modified human natural killer cells to treat cancer |
| AU2018269194B2 (en) * | 2017-05-15 | 2025-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
-
2020
- 2020-10-21 JP JP2022523383A patent/JP2022553292A/ja active Pending
- 2020-10-21 AU AU2020371628A patent/AU2020371628A1/en active Pending
- 2020-10-21 EP EP20879537.7A patent/EP4048292A4/en active Pending
- 2020-10-21 WO PCT/US2020/056723 patent/WO2021081133A1/en not_active Ceased
- 2020-10-21 US US17/770,585 patent/US20220362299A1/en active Pending
- 2020-10-21 CA CA3155246A patent/CA3155246A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7836847B2 (ja) | 二重特異性キメラ抗原受容体およびその治療的使用 | |
| Cochlovius et al. | Cure of Burkitt’s lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3× CD19 tandem diabody, and CD28 costimulation | |
| TWI706960B (zh) | 能夠結合cd19和cd3的雙特異性雙抗體及其用途 | |
| US5674492A (en) | Method of preventing or treating disease characterized by neoplastic cells expressing CD40 | |
| JP4448282B2 (ja) | ヒト癌を処置するのに有用なキメライムノレセプター | |
| EP3623388A1 (en) | Bispecific recombinant protein and use thereof | |
| IL279146B2 (en) | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
| JP7227630B2 (ja) | Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用 | |
| JP7404279B2 (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| AU2004242847A1 (en) | Pharmaceutical composition comprising a bispecific antibody for EpCAM | |
| KR20050108349A (ko) | 영속적인 티 세포 반응을 유도하는 삼량체 폴리펩티드 구조물 | |
| CN113045657B (zh) | 一种人源化抗人bcma单克隆抗体及其car-t细胞 | |
| JP2021525068A5 (https=) | ||
| WO2024078479A1 (zh) | 一种异源二聚体融合蛋白及其应用 | |
| CN114075287B (zh) | 人源化bcma抗体和bcma-car-t细胞 | |
| JPWO2021081133A5 (https=) | ||
| ZA200508279B (en) | Pharmaceutical composition comprising a bispecific antibody for epcam | |
| CN120826234A (zh) | 抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法 | |
| CN110339364A (zh) | Lgr4/rspo阻断剂与抗免疫检查点抑制剂联合用于肿瘤的免疫治疗 | |
| CN112321712B (zh) | 抗Tim3的抗体、嵌合抗原受体及其应用 | |
| EP4566619A1 (en) | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal | |
| TW202607043A (zh) | 多功能融合多肽 | |
| WO2025247196A1 (zh) | 一种多功能融合多肽 | |
| HK40125822A (en) | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal | |
| KR20250133125A (ko) | Gpc3을 표적으로 하는 키메릭 항원 수용체 및 cd276을 표적으로 하는 키메릭 항원 수용체를 발현하는 면역 이펙터 세포 및 이의 용도 |